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Summary
CD146 is an adhesion moleculep resent on endothelialc ells throughout the vascular tree.CD146 is also expressedbycirculating endothelialcells (CECs) widelyconsideredtobemature endothelialcells detachedfrominjured vessels.The discovery of circulating endothelialprogenitor cells(EPCs)originating from bone marrowp romptedu st oi nvestigate whetherC D146 circulating cells could also contains EPCs.Wetestedthis hypothesis using an approach combininge limination of CECs by an adhesion step, followedbyimmunomagnetic sorting of remaining CD146 + cells from the non adherent fractionofcordblood mononuclear cells.Whencultured under endothelial-promoting conditions,these cells differentiatedaslate outgrowth endothelial colonies: they grew as ac obblestone monolayer,wereu niformlypositivefor endothelialmarkersand didnot expressleukocyte antigens.They highlyproliferatedand were expanded in long-term culturew ithout alterations of their phenotypic and Keywords CD146, angiogenesis, myocardial infarction, circulating endothelial cells,progenitor endothelialcells functional properties (DiI-ac-LDL uptake, wound repair, capillary-liken etwork formation,a nd TNFα response). Moreover, these cells colonized aM atrigelp lug in immunodeficient mice (NOD/SCID). Finally, using 4-colorf lowc ytometry analysis of purifiedC D34+ cells,wec learly discriminated, CD146 + EPCs (CD146 
Introduction
CD146isanadhesion molecule belonging to the immunoglobulin superfamily. We previouslys howedt hat CD146 is at ransmembrane glycoproteinconstitutively expressed on vesselwall endothelialc ells, independentlyo ft he vesselt ype (1, 2) . Concentrated at the endothelial junction (3),C D146 is involved in intercellular cohesion (3) and signaling (4, 5) . We and othersalso demonstrated thatC D146 is expressed by the circulating endothelialc ells (CECs) widelyc onsideredt ob en on-hematopoietic cells with ap henotype of mature endothelial cells that enterthe circulation as aresultofshedding from injured vessel walls (6) . Consequently,the capture of CD146 immunobeads has become the most commonlyusedmethodfor quantification of blood CECs. IncreasednumbersofCECs have beenreported in awide variety of diseases associated with vascularinjury (7) (8) (9) (10) (11) . CECsprovide useful information for studying endothelialalterations (12) , as theymay represent damaged,necrotic,apoptotic (13, 14) or viable (15) endothelial cells and could possess procoagulant or proinflammatoryproperties (12) .
In addition to mature CD146 + CECs,a dult blood also contains bone marrowd eriveda ngioblast-likec ells (16) . Thefirst studiesr eported by Asahara et al (17) identified ap eripheral blood circulating CD34 + cellpopulation that canparticipate in postnatal neovascularization. By chromosomal analysis, Lin et al (18) have shown thatendothelial colonies developingafter 3 weeks of cultureofperipheral blood from sex-mismatchedbone marrowt ransplanted recipients were of donork aryotype and thus differentiatedfrom bone marrow-derivedcells. Sincethese pioneering studies, numerous reports have characterized circulating mononuclear blood cells that possess the ability to differentiate in vitro into cells with endothelial-likef unctional characteristics and geneexpression pattern. Since these cells specificallyh ome into sites of active angiogenesis and contribute to neovascularization in regenerating tissue,theyw ere commonly referred to as endothelialp rogenitor cells (EPCs).H owever,i t has become obvious that theyrepresent an heterogeneouspool of cells differing in the proliferative potential, phenotype and the timeofappearance of their in vitro endothelialprogeny (19, 20) . By contrast to mature CECs, indicatorso fe ndothelial injury, circulating EPCs represent markers of vascularr egeneration. Impaired mobilization or adecreased EPCnumber wasshown to correlate with cardiovascularrisk factorsand could contribute to endothelial dysfunction and cardiovasculardiseaseprogression (21) (22) (23) .
The coexistence of mature CECsand EPCswith overlapping antigenic features in humanblood raises considerable scope for their duali dentification. Although CD146 is currentlyu seda s the dominant marker of CECs in numerousreports(6), recent indirect observations suggestedthat CD146 could also be expressed on circulating EPCs (18) . However, direct evidenceofcirculating CD146 + EPCs is stilll acking.I nt his study,w ed emonstrated forthe first time thatincord blood,inaddition to mature CECs, CD146 + cells contain as ubpopulation of non-adherent cells giving rise to cells with morphologic, phenotypic and functionalp ropertieso fl ateo utgrowth EPCs. A4 -color flow cytometrya nalysis of purified CD34 + circulating cells enabledt he separate identification of CD146 + CECs and CD146 + EPCs,in cord-and peripheral blood of healthysubjects and patients with acute coronarys yndromes, therebyp roviding ap romising tool for the monitoring of vascularinjury/regeneration processesin clinical situations.
Materials andmethods
Collection of blood samples and isolation of mononuclearcells Umbilical cord blood samples (30-50 ml) were collected from donors in compliancew ith French legislation in as terile tube containing heparin. In addition, a2 0m ls ampleo fp eripheral blood collected in heparinizedt ubes waso btained from 5p atients, 48 hours after myocardiali nfarction and from 5a gematchedh ealthyv olunteers. Informed consent waso btained from all subjects. Circulating mononuclearcells (MNCs) were obtainedb ydensity gradient centrifugation. Briefly, blood was diluted in phosphate-bufferedsaline containing 2mMethylene-diaminetetraacetic (PBS/EDTA) and layered over lymphocyte separation medium (Eurobio, LesUlis, France) for30minutesat 1600 rpmand washedthreetimesinPBS/EDTA. (3) . Cells were seeded on gelatin-coated culturep latesa nd growninEGM-2 medium.All the cells were maintainedunder standard conditions (humidified atmosphere, 5% CO 2 ,37°C).
Growth curves CD146
+ late EPCs appeared as asmall compact clusterofcells about 10 days after plating. At day1 8, isolatedc olonies (one colonyp er well) were trypsinized. Cells of each colonyw ere replatedo na3 5m mp late (P1). One week later( day2 5), confluent cells were trypsinized (P2),counted and re-plated in a T75 flask. Subsequently,c onfluent cells were trypsinized, counted and re-platedinT75 flasks everyfivedaysuntil passage 12 (day7 5). Growth curvesf or each initial individual colony were determined. Capillary tubeformation in Matrigel 250 µ lofcold Matrigel  (BDBiosciences,BedfordMA) were added to 24-well plates. After30minutesat37°C,1x10 6 CD146 + EPCs (P4, P8, and P12)were added with 500 µ lofEGM-2 medium. Twelve hours later,wells were examinedand picturesofrepresentativef ields were takenu nder an inverted microscope (Eclipse TE2000-S, Nikon).
Quantitative flowcytometry

Wound repair
ConfluentC D146 + late EPC monolayers on gelatin-coated 24-well cultureplatesw ere wounded with ayellowtip, washed withRPMI and completed with EGM-2, EGM-2withoutgrowth factorsorEGM-2 withoutserum.All experiments were performed on wounds of equivalent sizes.Cellwound repair wascalculated, using video microscopyc oupled with as oftwares ystem allowing image analysis (Biocom, LesUlis, France),bysubtracting the wound area measuredafter 7hours of incubation from the area of the original wound (measured at time0 ). Results were expressed as ap ercentage of the area of the originalw ound, consideredas100%.
Immunocytochemistry analysis
Cells cultured in the chamber slides were washedtwice in PBS, fixedfor 10 minutes in 2% paraformaldehyde and incubated in a blocking solution (PBS/BSA 4%) for 1h our at room temperature.Immunostaining wasperformed using primary antibodies directedagainst humanCD144,human CD31, and human vWF (Dako, Trappes,F rance). Subsequently,t he slides were rinsed three timesinPBS/BSA and incubatedwith appropriate secondaryantibodies for 30 minutes at room temperature. Controls includedreplacement of primary or secondaryantibody with PBS. To detect acetylatedlow-density lipoprotein (LDL)uptake, cells were incubatedw ith DiI-ac-LDL (Molecular Probes,E ugene OR). Slides were examinedunder afluorescence microscope.
Forimmunocytochemistryanalysis of immaturecirculating cells, CD133 + cells were purified fromc ord blood MNCs by magnetic cells orting using microbead-conjugateda ntibodies following the manufacturer'sinstructions (MACS;MiltenyiBiotech).Freshly isolatedCD133 + cells were thenincubated with 20 µl of FITC conjugatedCD146 mAb (Sendo-1,Biocytex) and 20 µl of PE conjugated CD133m Ab (CD133/2, AC141, Miltenyi Biotec)for 20 min at 4°C.After twowashes,cells resuspended in PBS/BSA 0.1%, were observedunder fluorescence microscopy.
Matrigelplugassay 300 µ lo fM atrigel, phenol redf ree, re-liquefied at 4°Cf or 24 hours, were mixed with 1 µ gFGF2(PeproTech EC,London, UK) andi njected subcutaneously into NOD/SCID mice. 24 hours later, NOD/SCID micewereengrafted in thetail vein with 5.10 5 EPCs amplified (P4)from CD34 + or CD146 + cord blood cellsor with 5.10 5 HUVECs (P4). The experiment wasperformedtwice with four mice under each setofconditions. Twoweeksafterinjection, tissues containing the Matrigelp lug were removeda nd frozen.Matrigel cryosections were prepared. Human cellsw ere visualized by using the Ve ctorMOM kit(AbCys, Paris, France) following the manufacturer'si nstructions on Matrigels ections andwith primaryantibody against CD31, previouslyshown to be specific to humanc ells( 36), andt henw ith an appropriate secondary antibody.S ections were examinedu nderafluorescence microscope (Leica, Rueil-Malmaison,France). 
Four-color flowcytometryanalysis
Statisticalanalysis
Data are expressed as mean±standard errorofthe mean(SEM). Statistical analysis wasperformed with Prism software (GraphPadS oftwareI nc., San Diego, USA). Significant differences were determinedu sing Student'sp aired tt esto rb ya nalysis of variance (ANOVA )f ollowedb yaB onferroni test. Apv alue lowerthan 0.05 wasconsideredsignificant.
Results
Non-adherent CD146 + cells isolatedfromcordblood displaycolony-forming capacity
To investigatewhetherCD146 couldidentify EPCs, we performed a24-hour pre-plating of cordblood MNCs allowingremoval of adherentCD146 + CECs.Subsequently, the remaining non-adherent CD146 + cells were sorted by immunomagnetic separation and cultured in endothelialinductive conditions.Adherent colonies could be observedafter alatencyperiod of 9-11 days (Fig.  1A) . These cellsgrewinclusters and had acobblestone appear-ancesimilartothat of culturedHUVECs. Theyrapidlyexpanded from sparse cellstocolony-forming monolayers (Fig. 1B) .The number of CD146 + cell-derivedc olonies varied between samples. Amaximum of 9colonies could be generated from the 6x10 4 to the 9x10 4 CD146 + cells plated, corresponding to aplating efficiencyo fa pproximately1 :10 4 cells. Consequently, the number of late outgrowths of CD146 + cells cultured in EGM-2 wasestimatedper colony (Fig. 1C) . It wasapproximately2x10 4 after 18 days of culture(passage 1; Fig. 1A) ,and over 2.5x10 12 cells after 75 days of culture(passage 12).
Non-adherent cordblood CD146
+ cells differentiate into late outgrowth EPCs On Day35ofculture (passage 4), the expression of endothelial and hematopoietic markers by CD146-derivedcolonies wasanalyzed by flow cytometry. Endothelial differentiation wasattested by the strong expression of endothelial antigens such as PECAM-1 (CD31) and S-Endo1 (CD146) ( Fig. 2A) .A ll colonies also expressed CD34, VE-cadherin (CD144) and KDR. Among the inducible adhesive molecules,ICAM-1(CD54)was expressed at alow level, whereas VCAM-1 (CD106)expression wasn ot detected. These cells expressed neither CD45 nor CD133. Immunocytochemistryanalysis wasperformed to characterize further the phenotype of CD146 + -derivedcells. At day 35 of culture,t he colonies stained positivelyf or CD144 and CD31, with atypicalmembrane-associatedexpression concentrated at the intercellular junctions. The granulars taining obtainedwith vWFantibody suggested the presenceofW eibelPalade bodies ( Fig. 2B ). Takent ogether with morphological criteriaand the kinetics of cell growth, this endothelialphenotype provides evidencet hat non-adherent circulating CD146 + cells can differentiate into late outgrowthEPCs. The phenotypic properties of these cells(referred to as CD146 + late outgrowth EPCs)w ere further comparedtothose of late outgrowth EPCs derived fromcirculating CD34 + (referred to as CD34 + late outgrowth EPCs) and HUVECs, allthese cells being cultureduntil passage 4( Table1 ). These three typeso fe ndothelial cells displayed similar high levels of CD31a nd CD146 expression. Theyalso expressed CD54 and CD144 at comparablelevels. At this stageofthe cellular culture,the expressions of CD45 hematopoietic marker and CD133marker of immaturity were undetectable in allc ellt ypes. Notably,l evelso fC D34 and KDR expression were significantly higher in late outgrowth CD34 Table 2 ). The expression levels of endothelialantigens CD31, CD146, CD54, CD144 and KDR remained unchanged throughout expansion. Interestingly, even after 12 passages, these cells were still not activatedasevidenced by the absence of CD54,CD106 and CD62Einduction. Furthermore,C D34 expression progressively decreasedf rom passage 4t op assage 8a nd passage 12. Expression of CD45 and CD133 markers wasnever detected at anytime during culture. Thesed atas howt hat CD146 + late outgrowthE PCs maintain theire ndothelial phenotypic propertiese vena fter long-term expansion. Concerning their functional properties, CD146 + late outgrowthE PCs took up DiI-ac-LDL (Fig.3 A, left panel) and showed lectin-binding affinity (data not shown).Nosignificant difference in the DiI-ac-LDL uptake wasobservedbetween cells cultured until passage 8orpassage 12 as compared to passage 4. CD146 + late outgrowthEPCs made acapillary-likenetwork in Matrigeland no obvious difference wasobservedinthe capillary formation, whatever the cellpassage tested (Fig. 3B) . Moreover, endothelialm onolayers of CD146 + late outgrowthE PCs were scarred and wound repair wasmeasured under differentculture conditions including complete EGM-2medium versusEGM-2 medium withouts erum or growth factors. Figure 3C shows a representative fieldofaCD146 + late outgrowthEPC monolayer (passage4 )j ust after wounding (left panel; t=0) and after 7hours of incubation of the cells in complete EGM-2medium (middle panel; t=7h). Monolayerrepairb ypassage 4CD146 + late outgrowthE PCs wass ignificantly higher with complete EGM-2t han with growth factors/serum-freeE GM-2 (Fig.3 C; rightp anel). In allc ulture conditions, CD146 + late EPC repair capacity wassimilaratpassage 4, 8or12, demonstrating that the long-termc ultured cells retained their capacity to respond to serum or growth factors. Finally, up-regulation of CD54, CD62E and CD106 adhesion moleculesinducedbyTNFα stimulation of CD146 + late outgrowthEPCs remained unchanged between the three culturetimes, demonstrating thatlong-term expansion did not affect cytokineresponsiveness (Fig. 3D) .
Amplified CD146 + late outgrowth EPCs colonize angiogenicsites in NOD/SCIDmice CD146 + late outgrowthEPCs (P4), CD34 + late outgrowthEPCs (P4) or HUVECs (P4) were injected intravenously into NOD/ SCID miceb earing as ubcutaneous Matrigeli mplant diffusing FGF-2. Sincethis implant behavesa sa na ngiogenic target, we compared the capacity of the injected humanc ells to migrate toward this distant site throughthe blood circulation, and to colonize it. The presenceofhuman endothelial cells wasevidenced (Fig. 4) .This demonstrates that the injectedl ateo utgrowth CD146 + EPCs retained the capacityt o reach adistant angiogenic site and to participate in aneoangiogenic process. Circulating CD146 + EPCs can be discriminated from CD146 + CECs using4-color flowcytometryanalysis of cordand adultperipheral blood Since both matureCECs and circulating EPCs express CD146, we designeda4-color flow cytometryassaytodiscriminate between these twosubpopulations. CD34 + cells isolatedfrom cord blood MNCs were analyzed for CD45,C D34, CD133( or CD117) and CD146 expression. Arepresentativeexperiment is shown in figure 6 . According to CD45 expression, twodistinct subpopulations of CD34 + cells could be discriminated, respectivelyC D34 + CD45 + cells representing moret han 90% of the (Fig. 6A,g ateC ,r ed dots) ,a nd CD34 + CD45 -cells representing less than3%ofthe CD34 + cells (Fig. 6A,gateB,blue dots) . These twosubpopulations were then analyzed forthe co-expression of the endothelial markerCD146 and thes temc ellm arkers CD117o rC D133.A mong the CD34 + CD45 + cells, al ow percentage of cells co-expressed CD146 and CD133 or CD146 and CD117. This minor population wasd efineda sc irculating EPCs. Conversely, the CD34 Identical 4-color flow cytometryanalysis performed on adult peripheral blood showedthat these twoCD146 + endothelialsubpopulations could be discriminated in healthysubjects (n=5), but at al ower frequency thani nc ord blood. In each sample from healthysubjects the percentage of CD146 + CECs wasverylow, less than0.5% of CD34 + circulating cells, whereas the percentage of CD146 + EPCs washeterogeneousranging from 0.5to2% of CD34+ circulating cells (Fig. 7) . In five other patients with myocardiali nfarction (seed emographic features Table3 ), an exampleofclinical situations known to be associatedtoendothelial injuryand mobilization of bone marrowderivedEPCs, we observedincreased percentagesofCD146 + CECs,ranging from 1.2t o9%o ft he circulating CD34 + cells. Thep ercentageso f CD146 + EPCs were alsoincreased and variablesaccording to patients ranging from 2.3% to 5.1 %o fc irculating CD34 + cells (Fig. 7) .Astatistical analysis demonstrated as ignificant increaseofboth CD146 + CECs and EPCs in patients withMIas compared to normalindividuals. ForCD146 + CECs,the percentagesofCD34 + circulating cells were 4.36 ±1.47% versus0.26 ±0.07%, p<0.05 (MI versusnormal). ForCD146 + EPCs,the percentagesofCD34 + circulating cells were 3.66%±0.43% versus 1.06 ±0.21%, p<0.001 (MI versusnormal).
Circulating
Discussion
In this study, we provide evidencefor the heterogeneity of circulating CD146 + cells by documenting for the first time that, beside well-recognized matureCECs,theyinclude apopulation of immatureEPCs that mayplayarole in postnatal vesselgrowth.
CD146iscurrentlyrecognized as amarker of CECs detached frominjuredblood vessels in variousclinical situations (12) . The possibility that CD146could also identify circulating EPCs has sufferedfrom contradictorydata. In vasculitis (9)and hematopoietic stemcelltransplantation (24)circulating cells captured using CD146-immunobead didn eitherg rowi nc ulture nor stained for CD133. Conversely, the expression of CD146 has beenreported on CD34 + FGFR1 + circulating cells yielding small round cellswith lowgrowthpotential in culture (25) .However, no direct link wasestablished between circulating CD146 + cells and the generation of outgrowthe ndothelial colonies. In our study,CD146 + cells were purified fromcord blood after apreadhesion step ensuring elimination of highly adhesivem ature CECs.The endothelial features of the remaining non-adherent CD146 + cells were evidenced in endothelial-specificculture. In these conditions, these cells slowlyadhere, then give rise to colonies developingafter long term culture(2to3weeks)and displaying cobblestone morphology,high proliferativecapacity,endothelial phenotype and functional properties(DiI-ac-LDL uptake, tube formationi nM atrigel and wound healing assays). Thus, these CD146 + derived cells fulfilledthe typical features of late outgrowth endothelial cells.Theyd iffered from EPCs derivedf rom shortt ermc ulture of circulating MNC that aree n- dothelial-likec ells with remaining myeloidm arkers,s pindle shapeda ppearance and lowp roliferativep otential (19, 20, 26, 27) . Converging data have demonstrated that late outgrowth endothelial colonies originate from angioblast-likec irculating cells expressing CD34 and CD133 (34) (35) (36) . Here,w eshowthat cordblood non-adherent CD146 + cells give rise to late outgrowth endothelialc ells sharing similarp ropertiesw ith thosed erived from the non-adherent CD34 + population. These data strongly suggest thatt hese non-adherent circulating CD146 + cells are a sub-population of the CD34 + progenitors. Consistently, a4-color cytometrya nalysis of selectedC D34 + cells from cord and peripheral blood clearly discriminated betweent wo subsets of circulating CD146 + cells. Thef irst population co-expressed CD146 and CD34 butw as negative for the pan-hematopoietic marker CD45 and fort he stem/precursor cell markers CD133 and CD117. This cellpopulation, whichw as eliminatedb yadhesion of mononuclearc ells to plastic dishes,c orresponded to mature CECs. Interestingly, asecondCD146 + population, which wasnot removedb yapre-adhesion step, expressed both CD34 and CD133 (or CD117). This result provides further evidencefor the existenceo fc irculating CD146 + EPCs representing as ubpopulation of the CD34 + CD133 + precursors yielding late outgrowth EPCs. We also observed thatt he circulating CD146 + EPCs expressed the CD45 antigen. The expression of hematopoietic markeroncirculating CD146 + progenitors is consistent with the close association of hematopoietic and endothelial lineages during ontogeny. The existenceo fac ommon precursor, calledhemangioblast, hasbeen demonstrated in adults (37) (38) (39) . These hemangioblasts share the same markers with the hematopoietic stemcells i.e.CD133,CD34, VEGFR2 (KDR), CD117 and CD45 (38) . Remarkably,as imilarp henotype is also displayedbythe circulating CD34 + cells thatgiverise to late EPCs (34,3 6) and by the subpopulation of blood CD146 + late EPCs identifiedinthis study.These data arecompatible with apossible expression of CD146 on hemangioblasts, an hypothesis also supported by the presence of CD146o nh ematopoietic neoplastic cells (40). Moreover, the expression of CD45, togetherwith the outgrowthpattern of CD146 + circulating EPCs highly suggested thatt hese cells were of bone marrow origin (18) and not originated from vesselwalls as recentlydemonstrated forall the hierarchyofEPCs residing in vessellining endothelium (41) .
Theexpression of CD146 on circulating late EPCsmay have implications regarding the roleo ft his molecule in endothelial stem cell biology.Our group (3) (4) (5) and others (42, 43) showed thatCD146 is involved in the control of migration,proliferation and endothelialmonolayerformation via its functional connection with structural and signaling networks. More recently, its importanceh as been evidenced in normala nd tumoral vessel growth by experiments showing that CD146 inhibition reduced angiogenesis and tumor growth in vivo (44) .These data suggest that CD146 could be involved in neovascularization mediatedby endothelialprecursors.
Experimental evidences supportthe use of EPCsand CECs as biomarkers of cardiovascularrisk (6, (21) (22) (23) . Thus considerable concernhas emerged fortheir separate identification. Our data clearly demonstrated that CD146 is not onlyam arker of CECs butalso identifiesEPCs in normal and pathological adult humanblood.These resultshavesignificant implication for the identification of circulating cells expressing CD146. Regarding CD146immunomagnetic approaches commonlyusedfor CECs determination, additionalc riteria, togetherw ith CD146 expression, became requireds uch as size,a bsenceo fi mmature antigenexpression, or lackoflong termcolonyforming capacity.Interestingly, microscopic analysis of cordb lood immature cells coexpressing CD146 and CD133s howedt hat these cells looked significantly different from mature CECs, characterized by morphologic features of differentiatedcells and asizehigher than20 µ m(6). By contrast, the size of immatureCD146 + cells did not exceed 10 µ mwith an appearance of homogeneous round cells, indicating thatt heyc an noti nterfere with usual enumeration of CEC if morphological qualitiesare takeninto account. Alternatively,w ed emonstrated here thatu sing 4-color cytometrya nalysis, CD146 + EPCs canb es imultaneously enumerated butp henotypicallyd iscriminatedf rom CD146 + CECs (CD146 + CD34 + CD45 + CD133 + cells and CD146 + CD34 + CD45 -CD133 -cells, respectively). This wasillustrated in healthy subjectsa nd in patients with myocardiali nfarction, ac linical situation known to both alterendothelium integrity (8) and mobilizeEPCs from bone marrow (45, 46) . Va riationsinthe relative proportions of the twoC D146 + circulating cells ubsets within each group could be observed. It could thus be proposedthat the vascularpotential of individuals is reflectedb ythe balance betweent he CD146 + EPCs,h allmarks of regeneration,a nd CD146 + CECs,markers of endothelialinjury. In anormal situ-ation, this balancecould be in favorofregeneration whereas in patients with myocardialinfarction alterations of these twosubsets mayattest to the extent of the vascularinjuryand the associatedangiogenic response. The separate measurement of the two circulating CD146 + subpopulations using four-color flowcytometryanalysis mayprovide apromising tool for monitoring the vasculari njury/regeneration processesi nc linical situations. This hypothesis needs to be clearly establishedinfuture studies on larger cohorts of patients.
In conclusion, our study establishesthat CD146 + blood cells contains both mature and progenitor endothelial cells with significant implications for the separate measurement of these two subpopulations in clinical settings. In addition, the identification of CD146 as amarker of circulating EPCs providesanewmolecular tool for EPC isolation/ amplification and opens up new perspectivesfor arole of CD146 in endothelial stem cell biology.
